Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pharmaron-beijing-co-ltd" target="_blank" data-smartkarma-citation="entities:28428:1" rel="noopener">Pharmaron Beijing (3759 HK)</a> announced the placement of 58.4M shares for subscription at HK$22.82 per share.</li>
<li>Pharmaron intends to use the proceeds majorly to enhance capabilities of its laboratory services, drug process development, manufacturing facilities, alongside debt repayment and working capital purpose.  </li>
<li>Current market price of the stock (HK$23.84 on 15th January 2026) makes the placement offer attractive. Long-term growth prospects remain bright given the robust outlook and strong order generation capabilities.</li>
</ul>



Pharmaron Beijing (3759 HK) announced the placement of 58.4M shares for subscription at HK$22.82 per share.
Pharmaron intends to use the proceeds majorly to enhance capabilities of its laboratory services, drug process development, manufacturing facilities, alongside debt repayment and working capital purpose.  
Current market price of the stock (HK$23.84 on 15th January 2026) makes the placement offer attractive. Long-term growth prospects remain bright given the robust outlook and strong order generation capabilities.


Pharmaron Beijing (3759 HK): Placement Looks Attractive Given The Outlook and Growth Prospects

APAC IPOs & Placements, Aequitas Research

Nicholas Tan

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pharmaron-beijing-co-ltd-a8e38476-30ac-461e-9c7d-16ba5f06f997" target="_blank" data-smartkarma-citation="entities:28277:1" rel="noopener">Pharmaron Beijing (300759 CH)</a> is looking to raise US$175m in its primary offering. </li>
<li>The company plans to use the proceeds for project development, repayment of bank loans and as working capital.</li>
<li>In this note, we will talk about the placement and run the deal through our ECM framework.</li>
</ul>



Pharmaron Beijing (300759 CH) is looking to raise US$175m in its primary offering. 
The company plans to use the proceeds for project development, repayment of bank loans and as working capital.
In this note, we will talk about the placement and run the deal through our ECM framework.


Pharmaron Beijing Placement: Shares Had a Good Start This Year

Thematic (Sector/Industry)

<ul>
<li>Fosun Pharmaceutical initiated Phase 2 trial of FXS7553 for COPD in China. CSPC Pharma’s mpox mRNA vaccine candidate obtained clinical trial approval from the FDA.</li>
<li>Akeso secured NMPA approval for ivonescimab, in combination with chemotherapy, for the treatment of first-line squamous non-small cell lung cancer (sq-NSCLC). This indication marks ivonescimab’s third major approval.</li>
<li>Daiichi Sankyo’s Enhertu got China approval for the first-line treatment of breast cancer. Peptidream marked a milestone following the initiation of Phase 1 study for two radioligand therapies by Novartis.</li>
</ul>


Fosun Pharmaceutical initiated Phase 2 trial of FXS7553 for COPD in China. CSPC Pharma’s mpox mRNA vaccine candidate obtained clinical trial approval from the FDA.
Akeso secured NMPA approval for ivonescimab, in combination with chemotherapy, for the treatment of first-line squamous non-small cell lung cancer (sq-NSCLC). This indication marks ivonescimab’s third major approval.
Daiichi Sankyo’s Enhertu got China approval for the first-line treatment of breast cancer. Peptidream marked a milestone following the initiation of Phase 1 study for two radioligand therapies by Novartis.


APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Asian Hedge Fund Manager, Long Short Equity, Macro

David Mudd

Cross Asset Strategy

<ul>
<li>The Hong Kong Alpha portfolio gained 5.79% in July, outperforming its benchmark by 0.30%.  The portfolio has outperformed Hong Kong indexes by 52% to 74% since inception.</li>
<li>The portfolio's largest exposures are in the industrial, financial, and technology platform sectors. The portfolio has no exposure to the materials or energy sectors.</li>
<li>The portfolio has generated a Sharpe ratio of 1.20 since inception, compared with 0.69 for the benchmark.  The portfolio's annualized mean excess return is 19.4%.</li>
</ul>


The Hong Kong Alpha portfolio gained 5.79% in July, outperforming its benchmark by 0.30%.  The portfolio has outperformed Hong Kong indexes by 52% to 74% since inception.
The portfolio's largest exposures are in the industrial, financial, and technology platform sectors. The portfolio has no exposure to the materials or energy sectors.
The portfolio has generated a Sharpe ratio of 1.20 since inception, compared with 0.69 for the benchmark.  The portfolio's annualized mean excess return is 19.4%.


Healthcare Analyst

Wilfred Yuen

<ul>
<li>BD&amp;L deal flows continue: 1) Dizal/AstraZeneca on EGFR inhibitor Zegfrovy, 2) Innovent/Spero on CD40L, 3) Insilico Medicine/Bora on AI drug discovery, 4) Hansoh/Avere on oral IL23</li>
<li>
Pharmaron and Joinn Lab provided 1H26 results previews. Hengrui's NewCo Braveheart files for IPO. Legend's Carvykti generated sales of USD657m (+49% YoY or +10% QoQ) in 2Q26.</li>
<li>
China’s outbound drug licensing deal value reached c.USD110bn in 1H26, setting another new historic high, per NMPA. Moreover, China approved 38 Class I new drug in 1H26.</li>
</ul>


BD&amp;L deal flows continue: 1) Dizal/AstraZeneca on EGFR inhibitor Zegfrovy, 2) Innovent/Spero on CD40L, 3) Insilico Medicine/Bora on AI drug discovery, 4) Hansoh/Avere on oral IL23

Pharmaron and Joinn Lab provided 1H26 results previews. Hengrui's NewCo Braveheart files for IPO. Legend's Carvykti generated sales of USD657m (+49% YoY or +10% QoQ) in 2Q26.

China’s outbound drug licensing deal value reached c.USD110bn in 1H26, setting another new historic high, per NMPA. Moreover, China approved 38 Class I new drug in 1H26.


China Healthcare Weekly Wrap (13-17 July)

China

Pharmaron is a premier life science service provider offering comprehensive research, development, and manufacturing services across the entire drug discovery, preclinical, clinical development, and commercialization process. The company's services encompass small molecules, biologics, and cell and gene therapy products. Pharmaron was founded in 2004 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmaron (3759 HK)

Pharmaron Beijing (3759 HK): Placement Looks Attractive Given The Outlook and Growth Prospects

Pharmaron Beijing announced share placement to boost capacity and debt repayment. Long-term growth prospects remain bright given the robust...

Tina Banerjee

Pharmaron Beijing Placement: Shares Had a Good Start This Year

Pharmaron Beijing is looking to raise US$175m in its primary offering. In this note, we will talk about the placement and run the deal through our...

Nicholas Tan

APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...

Tina Banerjee

HONG KONG ALPHA PORTFOLIO: (July 2026)

We made several adjustments to the portfolio yesterday. We sold the Baidu (9888) position since it hit our stop-loss level. We also sold the...

David Mudd

China Healthcare Weekly Wrap (13-17 July)

Key news this week 1) Dizal/AZ USD1.5bn deal on EGFR inhibitor, 2) Hengrui's NewCo BraveHeart files for IPO; 3) Pharmaron and Joinn 1H26 results...

Wilfred Yuen

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pharmaron Beijing (3759 HK): Placement Looks Attractive Given The Outlook and Growth Prospects

​Pharmaron Beijing announced share placement to boost capacity and debt repayment. Long-term growth prospects remain bright given the robust...

Tina Banerjee

Pharmaron Beijing Placement: Shares Had a Good Start This Year

Pharmaron Beijing is looking to raise US$175m in its primary offering. In this note, we will talk about the placement and run the deal through our...

Nicholas Tan

APAC Healthcare Weekly (August 16) – Akeso, Fosun Pharma, CSPC Pharma, Daiichi Sankyo, Peptidream

Akeso’s ivonescimab and Daiichi Sankyo’s Enhertu got additional indications approvals in China. CSPC Pharma’s mpox mRNA vaccine candidate got FDA...

Tina Banerjee

HONG KONG ALPHA PORTFOLIO: (July 2026)

We made several adjustments to the portfolio yesterday. We sold the Baidu (9888) position since it hit our stop-loss level. We also sold the...

David Mudd

China Healthcare Weekly Wrap (13-17 July)

Key news this week 1) Dizal/AZ USD1.5bn deal on EGFR inhibitor, 2) Hengrui's NewCo BraveHeart files for IPO; 3) Pharmaron and Joinn 1H26 results...

Wilfred Yuen

Pharmaron Beijing announced share placement to boost capacity and debt repayment. Long-term growth prospects remain bright given the robust...